Therapeutic Area Biomarker Director – Cardiovascular and Metabolism

Delivering clinical project and disease biomarker strategies and plans across the early through late phase within the Cardiovascular and Metabolism portfolio and support relevant mature assets in the late phase portfolio. Leading a dedicated matrixed group of Subject Matter Experts and project team representatives as well as key program stakeholders, to together develop biomarkers strategies for disease and/or assets across the Research-Development-Commercial continuum. Representing Biomarker Development on Cardiovascular and Metabolism early and late Disease Area Decision Boards to identify, develop, and drive cardiovascular and metabolic disease and compound mechanistic biology, and precision medicine approaches for the portfolio. Leading strategic translational data working groups centered on integrating and analyzing large-scale patient multi-modal data sets (omics, imaging, digital, etc.) to identify new indications, endpoints, and responsive patient subpopulations. Representing BMD line functions in Therapeutic Area Line Function committees for clinical protocol development and operational milestone reviews. Leading biomarker strategies and drive plans at the clinical team level as a Biomarker Strategy Lead. Lead and/or contribute to BMD/TM/BR wide initiatives e.g. genetics, inflammation, imaging depending on background and expertise. Stay up to date on clinical, disease, biology and scientific literature and competitor data for their respective disease areas. Implementing strategies in close collaboration with the BMD global organization which includes over 150 associates with expertise in all aspects of biomarker science i.e. genetics, genomics, molecular and cellular, digital devices, imaging and data sciences. Design and present the RDC biomarker strategy for transitioning and mature assets for late phase within their key pillar and ensuring study level alignment across the portfolio segment of focus.

This hybrid role can be based in Cambridge US, or Basel, Switzerland. Novartis is committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve.

• MD, MD/PhD, or PhD degree required, plus additional PhD/postdoc or equivalent level research

• Deep understanding of cardiovascular and metabolic disease epidemiology with particular emphasis on Atherosclerotic Cardiovascular Disease (ASCVD) that can be applied to questions of diagnosis, biomarker development and treatment monitoring strongly preferred

• Scientific excellence supported by recognized high quality publications; clinical and/or biological expertise in cardiovascular and metabolic diseases (Board certified or similar level preferred) with impact in ASCVD literature

• 5 plus years of independent leadership experience and external leadership/partnership in consortia and/or health authority initiatives

• Proven success in leading and partnering in multidisciplinary matrix teams across Pharma/biotech (clinical research thru healthcare applications), academic institutions, or commercial business functions including a mature biomarker strategy to support registration and/or launch

• Demonstrated ability to own an entire section of the portfolio as well as the phase package; Well-developed interpersonal skills with good presence and ability to influence and negotiate with senior leadership; experienced presenter and communicator

• Significant relevant experience after your MD/PhD/postdoc including quantitative expertise in biostatistics, bioinformatics, computer biology, statistical genetics, clinical imaging, machine learning, or data science; interpreting and publishing studies consisting of “omics” data e.g. genetics, genomics, proteomics; closely partnering with/leading data scientists

• Fluent in oral and written English; other languages e.g. German, French, Italian useful but not required